CYSTISTAT

Country: Spanja

Lingwa: Spanjol

Sors: myHealthbox

Ingredjent attiv:

hialuronato sódico

Disponibbli minn:

LABORATORIOS RUBIO, S.A.

Unitajiet fil-pakkett:

1 vial de 50 ml con 40 mg de hialuronato sódico

Manifatturat minn:

Mylan Institutional, Inverin, Co. Galway, Ireland.

Indikazzjonijiet terapewtiċi:

El deterioro de esta capa de GAG del epitelio de la vejiga puede anular su función de barrera y permitir la adherencia de bacterias, microcristales, proteínas e iones, o el tránsito de residuos solubles iónicos y no iónicos como la urea a través del epitelio. CYSTISTAT® ha demostrado ser útil en el tratamiento de: Cistitis rádica, Cistitis infecciosa, Cistitis intersticial, Cistitis hemorrágica.

Sommarju tal-prodott:

CYSTISTAT® es una solución estéril de Hialuronato Sódico para la reposición temporal de la capa de glicosaminoglicanos (GAG) de la vejiga urinaria.

Karatteristiċi tal-prodott

STERILE SODIUM HYALURONATE SOLUTION
For temporary replacement of the glycosaminoglycan (GAG) layer in
the bladder.
DESCRIPTION: The glycosaminoglycan (GAG) layer on the luminal
surface of the bladder wall is believed to provide a protective bar-
rier against microorganisms, carcinogens, crystals and other agents
present in the urine and has been identified as the primary defense
mechanism in protecting the transitional epithelium from urinary irri-
tants.
1
Deficiencies in this GAG layer of the bladder epithelium may
destroy its barrier function and allow the adherence of bacteria, mi-
crocrystals, proteins and ions, or the movement of ionic and nonionic
solute residues (i.e. urea) across the epithelium.
2
CYSTISTAT
®
has
been developed to temporarily replenish the deficient GAG layer on
the bladder epithelium. The active substance is a highly purified
sodium
salt of hyaluronic acid.
EACH CYSTISTAT
® VIAL CONTAINS: 40 mg sodium hyaluronate.
DIRECTIONS: Instill the entire volume of this solution into the
bladder
after any residual urine has been removed. Discard any unused portion.
For best results CYSTISTAT
®
should be retained in the bladder for as
long as possible (a minimum of 30 minutes).
There is evidence that the GAG layer of the bladder is deficient in
cysti-
tis. This deficiency contributes to the clinical symptoms
2
in the diseases
such as interstitial cystitis,
3
cystitis caused by infections, trauma, uro-
lithiasis, urinary retention, neoplasia and radiation induced
cystitis.
4
To
alleviate cystitis associated with these conditions, it is recommended
that CYSTISTAT
®
be instilled into the bladder each week for 4-12
treatments and then monthly until symptoms resolve. The attending
physician, urologist or radiologist should direct any prophylactic use
of
CYSTISTAT
®
.
PRECAUTION: Do not administer to patients with known hypersensi-
tivity reactions. Discontinue use if adverse reactions are
experienced.
As no clinical evidence is available on the use of Hyaluronic Acid in
children, pregnant and lacta